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Abstract
Aim: This study aimed to assess the consistency and replicability of these process measures
during provision of the Italian Medicines Use Review (I-MUR). Background: Medication
review is a common intervention provided by community pharmacists in many countries, but
with little evidence of consistency and replicability. The I-MUR utilised a standardised
question template in two separate large-scale studies. The template facilitated pharmacists in
recording medicines and problems reported by patients, the pharmaceutical care issues (PCIs)
they found and actions they took to improve medicines use. Methods: Community
pharmacists from four cities and across 15 regions were involved in the two studies. Patients
included were adults with asthma. Medicines use, adherence, asthma problems, PCIs and
actions taken by pharmacists were compared across studies to assess consistency and
replicability of I-MUR. Findings: The total number of pharmacists and patients completing
the studies was 275 and 1711, respectively. No statistically significant differences were found
between the studies in the following domains: patients’ demographic, patients’ perceived
problems, adherence, asthma medicines used and healthy living advice provided by
pharmacists. The proportion of patients in which pharmacists identified PCIs was similar
across both studies. There were differences only in the incidence of non-steroidal anti-
inflammatory drug use, the frequency of potential drug-disease interactions and in the types
of advice given to patients and GPs. Conclusions: The use of a standardised template for the
I-MUR may have contributed to a degree of consistency in the issues found, which suggests
this intervention could have good replicability.
Background
Medication review is a cognitive pharmaceutical service (CPS) (Benrimoj et al., 2010) provided
by community pharmacists in a range of countries (Barbanel et al., 2003; Emmerton et al.,
2003; McLean et al., 2003; Bunting and Cranor, 2006; Mehuys et al., 2008; García-Cárdenas
et al., 2013). One of the earliest funded services is the Medicines Use Review (MUR) service
introduced in England in 2005, for which there is relatively little evidence to support either its
effectiveness (Wright, 2016) or cost-effectiveness (Centre for Policy on Ageing, 2014). A recent
systematic review and meta-analysis of randomised controlled trials of medication review
suggested that an isolated medication review has minimal effect on clinical outcomes, no effect
on quality of life and lacks evidence of economic outcomes, although studies have shown a
decrease in the number of drug-related problems (DRP), more changes in medication, more
drugs with dosage decrease and a greater decrease or smaller increase of the number of drugs
used (Huiskes et al., 2017).
Studies which have focussed on specific conditions, however, have consistently shown
positive outcomes. For example, in patients with asthma, studies in several countries have
shown that pharmacists can identify problems with medicines and intervene to improve
outcomes (García-Cárdenas et al., 2016), and that there is a need for such intervention. A
study in Denmark (Herborg et al., 2001) and more recent studies conducted in India (Gajanan
et al., 2015) and Vietnam (Nhu Nguyen et al., 2018) found that patients had poor knowledge
of asthma. A study in Germany found that the most common advice given to asthmatic
patients was education about their medicines (Schulz et al., 2001). Although many well-
designed studies (Narhi et al., 2000; Cordina et al., 2001; Herborg et al., 2001; Schulz et al.,
2001; Barbanel et al., 2003; Emmerton et al., 2003; McLean et al., 2003; Saini et al., 2004;
Mangiapane et al., 2005; Bunting and Cranor, 2006; Haahtela et al., 2006; Armour et al., 2007;
Mehuys et al., 2008; García-Cárdenas et al., 2013) have been carried out in asthma, very few
provided evidence of effectiveness (Armour et al., 2007; García-Cárdenas et al., 2013). A study
conducted by Armour et al. (2012) assessed the feasibility and sustainability of a CPS for
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patients with asthma, but did not assess consistency and replic-
ability. According to the Oxford Dictionary, consistency is the
quality of achieving a level of performance, which does not vary
greatly in quality over time; replicability represents the ability of a
scientific experiment or trial to be repeated to obtain a consistent
result.
In Italy, although the Government (Legge 69/2009 e D.LGS
153/2009) approved the provision of CPS in 2009, no services are
delivered by community pharmacies. In contrast to many other
countries, Italian community pharmacists are not permitted to
keep patient records of medication dispensed, hence reviewing
medicines is less feasible. Moreover, Italian pharmacists do not
receive training in clinical pharmacy as part of their under-
graduate training, and postgraduate training in this area is also
not widely available. The Italian Pharmacists’ Federation (FOFI),
recognising the extent to which Italian pharmacy had failed to
move forward with other countries in developing CPS, identified
the need for different types of evidence to be obtained locally
before any service could be commissioned. FOFI collaborated
with academic researchers to develop a programme of studies to
fulfil this need. The Italian Medicines Use Review (I-MUR)
project began in 2010 and took five years to complete. The
I-MUR developed was a structured approach to medication
review, based on the English service but with several key differ-
ences. Based on evidence of the benefits of CPS in asthma, this
condition was selected for the programme and the I-MUR
designed specifically for patients with asthma. It was constructed
using mostly closed questions to enable the community phar-
macists providing the intervention to easily gather the data
essential for demonstrating the type of evidence which could
ultimately support the continuation of such services.
The I-MUR programme involved three phases: Phase 1
(intervention testing), 2 (evaluation) and 3 (cluster randomised
controlled trial). Phases 1 and 3, in which pharmacists delivered
the I-MUR, were conducted in 2012–2013 and 2014–2015,
respectively. Phase 1 was a non-randomised study with no follow-
up, conducted in four cities in Northern Italy which identified the
potential for benefit. This study aimed to determine whether
pharmacists were able to undertake the process of completing an
I-MUR with asthmatic patients and upload data onto a web
platform. Both pharmacists and patients involved in Phase 1 were
excluded from Phase 3, which was a cluster randomised control
trial including an economic analysis, conducted in 15 regions
across the whole of Italy. Phase 3, reported elsewhere (Manfrin
et al., 2017), demonstrated that the I-MUR was both effective and
cost-effective. Results from the evaluation (Phase 2) which
obtained the views of pharmacists, patients and GPs on the
I-MUR service provided during Phase 1 have also been published
(Manfrin and Krska, 2018).
However, for a service to be commissioned and funded, there
should be demonstrable capacity to benefit (need), consistency
and replicability of the structures and processes which contribute
to clinical effectiveness should be assured (Donabedian, 1980). As
no previous studies had been undertaken in Italy of CPS, the
collection of process data was an important aspect of evaluating
delivery of the I-MUR intervention. For an intervention to
become standard practice, a degree of consistency is needed and
for a particular outcome to be achieved, the structures and pro-
cesses should be similar. Previous studies have shown that
delivery of a medication review intervention varies between
individual pharmacists (Krska and Avery, 2008; Hinchliffe, 2011).
We therefore examined key process measures which could
contribute to the effectiveness of the I-MUR intervention to assess
the potential consistency of delivery, in the absence of formal
fidelity testing, which is regarded as the extent to which a test
duplicates the actual conditions or task performed; the closer the
match, the higher the fidelity of the test. We also assessed the
potential need for the service (potential to benefit) by review of
the problems patients reported with their asthma and their
medicines.
Aims
The aims of this study were to assess the consistency and
replicability of I-MUR by:
(i) comparing the demographics, medications (active ingredi-
ents) used, self-reported adherence and problems with
asthma and medicines of patients involved in Phases 1
and 3 of the I-MUR programme;
(ii) quantifying and comparing the types of pharmaceutical care
issues (PCIs) and actions taken by pharmacists during the
provision of I-MUR in both phases.
Methods
Selection and recruitment of pharmacies, pharmacists and
patients
Local pharmacy organisations in each of the four regions (Phase
1) and 15 regions (Phase 3) invited all community pharmacists to
participate (using phone calls and emails). For those who
expressed interest in the study, a selection process was undertaken
to ensure that pharmacists all met pre-specified inclusion criteria,
which included a private room, internet connection and provision
of some services beyond dispensing from their pharmacy. Patients
were recruited by the pharmacists on the basis of either a diag-
nosis or prescription of medicines for asthma. Further details of
all inclusion and exclusion criteria for pharmacies, pharmacists
and patients have been published elsewhere (Manfrin et al., 2015).
The I-MUR intervention
The I-MUR involves a face-to-face consultation between phar-
macist and patient in a private room. The I-MUR was generally
based on the English MUR template, but a new more systematic,
structured interview template was developed, specifically for
asthma patients, which used closed questions allowing quantita-
tive data to be gathered easily. Questions in the template covered:
asthma symptoms, medicines used (active ingredients), problems
and adherence. The first version of I-MUR was developed by
A.M. for Phase 1, and was validated by eight Italian non-
participating community pharmacists. The results of the evalua-
tion (Phase 2) provided the opportunity to add two questions to
the I-MUR instrument before using it in Phase 3. All pharmacists
in both Phases (1 and 3) received training regarding asthma
physiopathology and clinical pharmacology from respiratory
physicians (1 h). A.M. provided 3 h of training in Phase 1 and 4 h
in Phase 3. The difference in the length of training was due to
higher complexity of Phase 3. The training provided was in
pharmaceutical care, in particular how to identify PCIs, which
could have an impact on the use of medicines and/or asthma
control and to provide appropriate advice to patients and
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recommendations to their GPs. The latter were based on the
individual pharmacists’ clinical judgements using all the data
gathered during the I-MUR. Pharmacists were also trained in the
use of the I-MUR template to gather data and in uploading it onto
the web platform. Use of this system enabled pharmacists to enter
patient-level data in Italy, which was then downloaded for ana-
lysis in the United Kingdom, thus avoiding the complexities of
paper-based data collection. In order to provide the I-MUR, the
pharmacists had to request details of all medicines patients were
using, due to the lack of patient medication records. For each
patient, pharmacists recorded: medicines used, responses to
closed questions on asthma, problems and adherence, PCIs they
identified and actions/recommendations they made.
Data analysis
Medications (active ingredients) were classified using the World
Health Organization (WHO) anatomic, therapeutic, chemical
(ATC) classification system. The frequency of use of three major
drug classes, non-steroidal anti-inflammatory drugs (NSAIDs),
ace-inhibitors (ACE-Is) and β-blockers not recommended in
asthmatic patients was determined. The number of PCIs identi-
fied and actions taken during the I-MUR service provision were
classified by the pharmacists using the methods of Krska et al.
(2002) before adding to the web platform. This classification
system, which has been used in medication review studies in
England (Krska and Avery, 2008), was deemed sufficiently simple
for use by the Italian pharmacists.
Comparisons between the data obtained from Phases 1 and 3
were made using three non-parametric techniques. (χ 2) for
independence (Pearson’s χ 2) was used when comparing the
relationships between two categorical variables, and when each of
these variables could have had more than two or more categories.
Fisher’s exact test for independence was used when the frequency
was below five. χ 2 test for goodness-of-fit was used with catego-
rical variable when comparing the proportion of cases from a
sample with hypothesised of those obtained previously from a
comparison population. Owing to the number of hypotheses
Table 1. Patients’ demographic and asthma active ingredients
Phase 1 Phase 3
n % n % P-value
Gender 0.0237
Female 491 54.9 480 58.8
Male 404 45.1 336 41.2
Total 895 816
Age range 0.0060
18–40 170 19.1 195 23.9
41–50 128 14.3 156 19.1
51–60 146 16.4 153 18.8
61–70 185 20.7 159 19.5
Over 70 263 29.5 153 18.8
Total number of patients 892 816
Missing 3
Active ingredients
Corticosteroids (eg, beclomethasone) 660 73.7 638 78.2 0.0088
β-2 agonists long-acting (eg, salmeterol) 637 71.2 617 75.6 0.0102
β-2 agonists short-acting (eg, salbutamol) 488 54.5 398 48.8 0.0374
Antimuscarinic bronchodilators (eg, ipratropium) 216 24.1 142 17.4 0.0012
Leukotriene receptor antagonists (eg, montelukast) 146 16.3 231 28.3 0.0010
Theophylline 28 3.1 29 3.6 0.1407
Cromoglicate and nedocromil 4 0.4 14 1.7 0.0153b
Omalizumab (only prescribed by special centres) 1 0.1 6 0.7 0.0589b
Total number of patients 895 816
χ 2 with Bonferroni adjustment 0.05/53 0.0009
aStatistical significant difference.
bFisher’s exact test with Bonferroni adjustment.
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tested (53 items), the Bonferroni correction was adopted, as
suggested by Goldman (2008), resulting in a level of significance
of P= 0.0009. The analysis was conducted using Microsoft Excel
version 2016 and SPSS version 24.
Findings
Demographic details
In Phase 1, four Italian regions and four specific locations (towns)
were involved: Piemonte (Torino), Toscana (Pistoia), Lombardia
(Brescia) and Veneto (Treviso). The number of pharmacists
enrolled in Phase 1 was 74 and they recruited 895 patients. Phase
3 was powered to detect a clinically significant difference in ATC
score, using a large number of pharmacists across Italy, to
minimise the effect of inter-pharmacist variation on the primary
outcome. Therefore, 201 pharmacists and 816 patients completed
Phase 3. The number of regions involved in this phase was 15:
Trentino Alto Adige, Lombardia, Sicilia, Puglia, Sardegna, Pie-
monte, Valle d’Aosta, Veneto, Friuli Venezia Giulia, Toscana,
Emilia Romagna, Marche, Abruzzo, Lazio and Campania.
Patients recruited to both studies showed similar gender and
age distributions, spanning a large range of ages (Table 1).
Medicines used (as active ingredients)
The median number of all active ingredients used by patients
before receiving the I-MUR was 5.0, in both Phases 1 and 3. No
statistically significant differences were found across the two
populations in the active ingredients used for treating asthma
(Table 1), with the most common active ingredients being cor-
ticosteroids (73.7%, Phase 1; 78.2%, Phase 2) and long-acting β-2
agonists (71.2%, Phase 1; 75.6%, Phase 2), whereas the least
common was omalizumab (0.1%, Phase 1; 0.7% Phase 2). Overall,
the proportion of patients using active ingredients considered to
be inappropriate in asthmatic patients (ACE-I, β-blockers and
NSAIDs) was slightly higher in Phase 3 compared with Phase 1,
but the difference was not statistically significant (Table 2).
Self-reported adherence and problems with medicines
Patients’ self-reported adherence to medications was low in both
phases: 51.4% (n= 460) in Phase 1 and 45.8% (n= 374) in Phase 3
Table 2. Pharmaceutical care issues (PCIs) and active ingredients
Phase 1 Phase 3
n % n % P-value
Type of PCIs
Education required 259 28.9 245 30 0.1617
Monitoring issues 216 24.1 165 20.2 0.0554
Discrepancy between dose prescribed and drug used 156 17.4 159 19.5 0.0613
Potential ineffective therapy 146 16.3 122 15 0.2055
Potential/actual compliance/adherence 128 14.3 112 13.7 0.2271
Inappropriate dose regimen 116 13 90 11 0.1252
Potential/suspected adverse drug reaction 101 11.3 122 15 0.0044
Potential drug-disease interaction 82 9.2 115 14.1 0.0002a
Inappropriate duration of therapy 53 5.9 42 5.1 0.1674
Untreated indication for therapy 40 4.5 32 3.9 0.1739
Repeat prescription no longer required 22 2.5 23 2.8 0.144
Drug use with no indication 19 2.1 29 3.6 0.0185
Others 2 0.2 0 0 0.5007b
Total number of patients 895 816
Active ingredients
ACE-I 114 12.7 90 11 0.1452
β-Blockers 64 7.2 68 8.3 0.0838
NSAID 261 29.2 340 41.7 <0.0001a
Total number of patients 895 816
χ 2 with Bonferroni adjustment 0.05/53 0.0009
ACE-I= angiotensin-converting-enzyme inhibitors; NSAID= non-steroidal anti-inflammatory.
aStatistical significant difference.
bFisher’s exact test with Bonferroni adjustment.
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(P= 0.0214; not statistically significant). Around a quarter of
patients in both studies perceived they had problems with their
asthma medications, whereas around three-quarters considered
they knew how to use them, considered they were working and
were effective (Table 3).
PCI identified and actions taken
Despite patients perceiving they knew how to use medicines, in
Phase 1 pharmacists identified at least one PCI in 543 (60.7%)
patients, a mean of 2.4 per patient among those with a PCI. In
Phase 3, 64.6% of patients (527/816) had a PCI with the mean
being 2.5 per patient. The three most common PCIs in both
phases were the same: education required, monitoring issues
and discrepancy between dose prescribed and drug used
(Table 2).
In both Phases, the most common type of action taken by
pharmacists was to provide drug information to patients. Overall,
there were very few differences between the two studies in the
types of actions taken by pharmacists to improve medicines use
(Table 4). The frequency with which advice regarding healthy
living was provided also showed no differences between the
phases. In particular, pharmacists provided advice to stop or
reduce smoking to 23 and 25% of patients in Phases 1 and 3,
respectively. The need to carry out monitoring was the most
frequent type of advice given to GPs in both phases, but was
slightly more common in Phase 3, as was the recommendation to
change a drug and other advice.
Table 3. Patients’ perceptions of their medications
Phase 1 Phase 3
n % n % P-value
How patients were getting on with their medications 0.8300
Did not have problems 640 72.2 573 70.9
Had some problems 227 25.6 217 26.9
Had lots of problems 19 2.1 18 2.2
Total number of patients 886 808
Missing 9 8
Did patients have enough knowledge and understanding about how
to take their medications?
0.4700
Knew how to take the medications fully 689 77.8 611 75.2
Knew how to take the medications partially 187 21.1 191 23.5
Did not know how to take the medications at all 10 1.1 10 1.2
Total number of patients 886 812
Missing 9 4
What did patients think about their medications? 0.4700
All were working 659 74.7 629 77.7
Some were working 180 20.4 149 18.4
None were working 6 0.7 3 0.4
Did not know 37 4.2 29 3.6
Total number of patients 882 810
Missing 13 6
Did patients think their medications were effective as they were expecting? 0.0020
Yes 667 75.6 627 77.2
No 130 14.7 80 9.9
Did not know 85 9.6 105 12.9
Total number of patients 882 812
Missing 13 4
χ 2 with Bonferroni adjustment. 0.05/53 0.0009
aStatistical significant difference.
bFisher’s exact test with Bonferroni adjustment.
Primary Health Care Research & Development 5
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1463423618000580
Downloaded from https://www.cambridge.org/core. University of Sussex Library, on 16 Apr 2019 at 13:25:43, subject to the Cambridge Core terms of use, available at
Discussion
The data obtained in Phase 1 were derived from a large sample of
patients, but a relatively small number of pharmacists in only four
northern Italian cities, where the cooler temperatures may have
an adverse effect on asthma control. In contrast, the findings from
Phase 3 involved a similar number of patients but recruitment
was spread over 15 out of 20 Italian regions, from the North to
the much warmer South, and almost three times the number of
pharmacists were involved. The similarities in the prevalence of
inappropriate medicines used, such as ACE-I and β-blockers,
perceptions of problems, adherence and smoking across the two
studies, however, suggests that the results obtained in Phase 1
were confirmed in Phase 3. Furthermore, a total of 53 items were
compared in this analysis, and only 15% (8/53) of them presented
a statistically significant difference. Thus, these results suggest the
need for an intervention, which could provide potential benefits
for patients with asthma.
The finding that around 50% of patients were adherent to
asthma treatment is in line with the results of a systematic review
(Engelkes et al., 2015), which found that adult adherence rates to
asthma treatment was between 30 and 70%. The relatively high
rates of smoking in patients with asthma are reflective of the high
national prevalence in Italy (21%) (Lugo et al., 2017).
The process measures recorded, PCIs identified and actions
taken, during delivery of the intervention, were also consistent
between the two phases. One possible reason for such consistency
is that the patient population was similar, despite the broad
inclusion criteria, but the use of a standardised, structured tem-
plate and similar training could also contribute to these findings.
Given that Phase 3 demonstrated the I-MUR to be both clinically
effective and cost-effective, it is reasonable to anticipate that,
provided the structures are consistent (training, private
area, other pharmacist inclusion criteria met) the processes
maintained through the use of a structured interview, the benefits
demonstrated in Phase 3 should be achieved in a commissioned
service.
The mean number of PCIs per patient of 2.5 and 2.4 in Phases
1 and 3, respectively, and the most common action taken by
pharmacists being patient education required in both populations
are similar to the studies in other European countries. A Danish
study conducted in 2001 (Herborg et al., 2001) found that the
most common DRP in asthmatic patients was poor knowledge of
asthma, suggesting that, as was found here, patient education was
required. A German study (Schulz et al., 2001) reported the most
common advice given to asthmatic patients by pharmacists was
drug information. This was also the most common recommen-
dation in a study in England of patients with multi-morbidity
(Krska et al., 2000), which used the same classification system for
quantifying PCIs and pharmacist actions. Other studies in multi-
morbid patients have, however, found a higher number of DRPs
(Brulhart and Wermeille, 2011).
The lack of consistency in provision of an intervention found
in some studies (Krska and Avery, 2008; Hinchliffe, 2011) is a
potential problem for a commissioned service. Greater standar-
disation of the intervention, using the mechanisms employed
here, may help to reduce such variation. Although it must be
acknowledged that structured questioning is somewhat contrary
to the open-ended approach to medication review advocated in
England, which seeks to improve patient-centred consultations
(Picton and Wright, 2013), the inclusion of selected standardised
questions into the process and recording of these data could help
to provide a greater degree of evidence, while still allowing for
individualised care.
Strengths and limitations
The data presented here involved 1711 patients and 275 phar-
macists, thus the combined data represent one of the largest
reports describing a pharmaceutical care intervention. The two
studies, Phases 1 and 3, were conducted at different times, in
different locations, by different pharmacists and with different
Table 4. Frequency of advice provided by pharmacists to patients and general
practitioners
Phase 1 Phase 3
n % n % P-value
Advice given to patients
Drug information provided 659 73.6 585 71.7 0.4560
Consult GP 355 39.7 355 43.5 0.0226
Change method of administration 119 13.3 192 23.5 <0.0001a
Change dose 86 9.6 94 11.5 0.0443
Change time of administration 54 6.0 64 7.8 0.0321
Stop non-prescription drugs 38 4.2 71 8.7 <0.0001a
Other 10 1.1 88 10.8 <0.0001a
Total number of patients 895 816
Healthy living advice to patients
Physical activity 344 38.4 332 40.7 0.0884
Diet and nutrition 329 36.8 368 45.1 0.0060
Weight management 236 26.4 234 28.7 0.0660
Smoking 204 22.8 203 24.9 0.0719
Alcohol 79 8.8 61 7.5 0.1397
Other 16 1.8 26 3.2 0.0159
Sexual health 11 1.2 21 2.6 0.0106
Total number of patients 895 816
Advice given to GPs
Carry out monitoring 471 52.6 491 60.2 0.0002a
Provide compliance/adherence aid 261 29.2 268 32.8 0.0197
Change dose 72 8.0 82 10.0 0.0330
Add a drug 71 7.9 46 5.6 0.0374
Change drug 53 5.9 91 11.2 < 0.0001a
Change computer record 33 3.7 21 2.6 0.0802
Stop a drug 29 3.2 27 3.3 0.1800
Other 18 2.0 68 8.3 <0.0001a
Total number of patients 895 816
Pearson χ 2 with Bonferroni adjustment 0.05/53 0.0009
aStatistical significant difference.
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patients, yet showed similar findings. The large sample sizes
included also support the generalisability of the results achieved
using I-MUR in Phase 3.
The data gathered during the I-MUR (medications used,
problems, PCIs and actions) were uploaded onto a web plat-
form by the pharmacists who conducted the I-MUR and it was
not possible to verify the accuracy of these. The classification of
PCIs and actions was dependent on the interpretation of the
pharmacists and these were not validated. However, this
approach did facilitate the conduct of two large-scale studies at
minimal cost and no problems were encountered in use of these
classification systems, despite the large number of pharmacists
involved.
Conclusions
A structured approach to medication review for asthma has the
potential to improve outcomes due to consistency in delivery and
there is potential to benefit from the I-MUR across Italy. It may
be appropriate to consider using a similar structured approach for
other conditions and in other countries. Involving pharmacists in
gathering patient-level data may be a useful strategy to help
generate the type of evidence suggested as being required to
support CPS such as medication review.
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Phase 3 have been deposited in the Kent Academic Repository (KAR url:
https://www.kent.ac.uk/library/research/kar/), after being treated in accor-
dance with requirements of the Data Protection Act (1998), that is anon-
ymised and stripped of any identifiable references to the participants.
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